

# Fosfomycin (injection)

NOT RECOMMENDED AS AN

ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.3. Reserve group antibiotics

EMLc

Codes ATC: J01XX01

|                              |   |
|------------------------------|---|
| Indication                   | Other specified bacterial diseases<br>Code ICD11: <a href="#">1C4Y</a>  |
| INN                          | Fosfomycin  |
| Type de médicament           | Chemical agent  |
| Groupes d'antibiotiques      | <span style="border: 1px solid red; padding: 2px;">R</span> RESERVE   |
| Type de liste                | Liste complémentaire (EML)<br>(EMLc)  |
| Formulations                 | Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection ; 4 g in vial (as sodium) powder for injection |
| Historique des statuts LME   | Ajouté pour la première fois en 2017 ( <a href="#">TRS 1006</a> )<br>Retiré en 2019 ( <a href="#">TRS 1021</a> )                  |
| Sexe                         | Tous  |
| Âge                          | Aussi recommandé pour les enfants   |
| Équivalence thérapeutique    | La recommandation concerne ce médicament spécifique   |
| Renseignements sur le brevet | Lire la suite <a href="#">sur les brevets.</a> ↗  |
| Wikipédia                    | <a href="#">Fosfomycin (injection)</a> ↗  |
| DrugBank                     | <a href="#">Fosfomycin</a> ↗  |

## Résumé des preuves et recommandation du comité d'experts

As part of the review of the AWaRe classification and EML listing of antibiotics, the Expert Committee recommended selected Reserve group antibiotics be listed as individual medicines on the WHO Model Lists when they have a favourable benefit-risk profile and proven activity against "Critical Priority" or "High Priority" pathogens as identified by the WHO Priority pathogens list. Refer to the 2019 recommendations for new indications for intravenous fosfomycin on the EML and EMLc.

